⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL286216 | 1.00 | — | — | |
| SCHEMBL963318 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL1456661 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL1901330 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL3530304 | 0.97 | ALDH1A1 (0.40) | — | |
| Hydrochloric Acid SCHEMBL1071510 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL20168170 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL20166247 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL20166172 | 0.95 | — | — | |
| SCHEMBL24335171 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026077418-A9 | ISOINDOLINE COMPOUND CONTAINING PHENYLETHOXYALKYLENEAMINE STRUCTURE, CONJUGATE THEREOF, AND USE THEREOF | 上海海雁医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20240197678-A1 | INHIBITORS OF THE PEPTIDYL-PROLYL CIS/TRANS ISOMERASE (PIN1) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| US-20230295131-A1 | INHIBITORS OF RHO-ASSOCIATED COILED-COIL KINASE | ANGION BIOMEDICA CORP. | 2023-09-21 | — | — | US | disclosed |
| US-20230295131-A1 | INHIBITORS OF RHO-ASSOCIATED COILED-COIL KINASE | ANGION BIOMEDICA CORP. | 2023-09-21 | — | — | US | disclosed |
| US-20230295131-A1 | INHIBITORS OF RHO-ASSOCIATED COILED-COIL KINASE | ANGION BIOMEDICA CORP. | 2023-09-21 | — | — | US | disclosed |
| CN-116209658-A | Inhibitors of RHO-associated coiled coil kinase | 安吉昂生物医药公司 | 2023-06-02 | — | — | CN | disclosed |
| EP-4185579-A1 | INHIBITORS OF RHO-ASSOCIATED COILED-COIL KINASE | Angion Biomedica Corp. (US) | 2023-05-31 | — | — | EP | disclosed |
| WO-2022197993-A1 | INHIBITORS OF THE PEPTIDYL-PROLYL CIS/TRANS ISOMERASE (PIN1) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-11377443-B2 | Pharmaceutical compounds | CellCentric Limited (GB) | 2022-07-05 | — | — | US | disclosed |
| CN-110049983-B | Pharmaceutical compounds | 细胞中心有限公司 | 2022-06-14 | — | — | CN | disclosed |
| US-20080146606-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| US-20080090811-A1 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-04-17 | — | — | US | disclosed |
| WO-2008034860-A1 | PYRROLO[2, 3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS IKK2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-03-27 | — | — | WO | disclosed |
| US-20080070923-A1 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-03-20 | — | — | US | disclosed |
| US-20080058369-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| US-7329752-B2 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7317022-B2 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists | THERAVANCE, INC. (US) | 2008-01-08 | — | — | US | disclosed |
| US-20070117796-A1 | Carbamate compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2007-05-24 | — | — | US | disclosed |
| US-20060276482-A1 | Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists | THERAVANCE, INC. | 2006-12-07 | — | — | US | disclosed |
| US-20060199839-A1 | Quinolinone compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2006-09-07 | — | — | US | disclosed |